Allopregnanolone-based treatments for postpartum depression: Why/how do they work?

Recent FDA approval of an allopregnanolone-based treatment specifically for postpartum depression, brexanolone, now commercially called Zulresso®, is an exciting development for patients and families impacted by postpartum depression and allows us to start asking questions about why and how this com...

Descripción completa

Detalles Bibliográficos
Autores principales: Walton, Najah, Maguire, Jamie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Articles from the Special Issue on Allopregnanolone role in the neurobiology of stress and mood disorders; Edited by Graziano Pinna
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838978/
https://www.ncbi.nlm.nih.gov/pubmed/31709278
http://dx.doi.org/10.1016/j.ynstr.2019.100198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838978/
https://www.ncbi.nlm.nih.gov/pubmed/31709278
http://dx.doi.org/10.1016/j.ynstr.2019.100198

Ejemplares similares